glp-1 obesity drug news today oct 2025 Genetics: How Genes Affect Appetite, Semaglutide, and Tirzepatide Response Poll: 1 in 8 Adults

This overlap highlights their promise as pharmacological analogues of exercise, and underscores the need for biomarker-driven, disease-specific trials to establish whether GLP-1RAs can deliver durable disease modification across the spectrum of neurodegenerative diseases

The guide on when weight loss begins on semaglutide gives context on where you are likely to be in the metabolic adjustment curve relative to a test, which helps you understand what side effects you might reasonably expect

Mathieu C, Dandona P, Gillard P et al (2018) Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial

Valensi P

[DOI] [PubMed] [Google Scholar] 20.Thethi TK, Pratley R, Meier JJ

A recent meta-analysis involving 32,884 patients from 19 randomized controlled trials further confirmed a 23% reduction in all-cause mortality associated with GLP-1RAs use (OR = 0.77) (Rivera et al., 2024)